Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03647267
Other study ID # DRCR.net Protocol AG
Secondary ID U10EY014231U10EY
Status Completed
Phase Phase 3
First received
Last updated
Start date October 16, 2018
Est. completion date August 6, 2020

Study information

Verified date September 2022
Source Jaeb Center for Health Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Eyes with idiopathic symptomatic vitreomacular traction (VMT) without a macular hole will be randomly assigned to 0.3-mL intraocular gas (C3F8) injection or sham injection to determine if pneumatic vitreolysis (PVL) is effective in releasing VMT.


Description:

Investigational Device: 0.3-mL intraocular gas (C3F8) injection Objectives Primary 1. To compare the proportion of eyes with central VMT release on OCT after pneumatic vitreolysis with gas injection versus observation (sham injection) in eyes with VMT without an associated macular hole. Secondary 2. To evaluate visual function outcomes at 24 weeks after gas injection is performed compared with sham injection. Study Design: Multi-center, randomized clinical trial


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date August 6, 2020
Est. primary completion date August 6, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. At least one eye meets the study eye criteria listed below. 2. Able and willing to provide informed consent. 3. Able and willing to avoid high altitude travel, including airline travel, until gas resolution (approximately 6 to 8 weeks). 4. For phakic patients, able and willing to avoid supine position until gas resolution (approximately 6 to 8 weeks). 5. Able and willing to wear wristband that informs any medical personnel that the patient has a gas bubble in the eye Exclusion A potential participant is not eligible if any of the following exclusion criteria are present: 6. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status that might preclude completion of follow-up) 7. Participation in an investigational trial within 30 days of randomization that involves treatment with any drug or device that has not received regulatory approval for the indication being studied at the time of study entry • Note: study participants should not receive another investigational drug/device while participating in the study 8. Known contraindication to any component of the treatment 9. Known allergy to any drug used in the procedure prep (including povidone iodine) 10. Potential participant is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the next 6 months following randomization 11. Anticipated surgery requiring anesthesia within the next 6 months following randomization • Participants cannot receive nitrous oxide until gas resolution 12. For women of child-bearing potential, pregnant at the time of enrollment • Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgement may be used to determine when a pregnancy test is needed. Study Eye Criteria The participant must have at least one eye meeting all of the inclusion criteria and none of the exclusion criteria listed below. A participant can have only one study eye. If both eyes are eligible at the time of randomization, the study eye will be selected by the investigator and participant before randomization. The eligibility criteria for a study eye are as follows: Inclusion 1. Vitreomacular adhesion on OCT that is no larger than 3000 microns with visible separation of the vitreous on either side as seen on horizontal and vertical scans, confirmed by central reading center Note: presence of epiretinal membrane is neither a requirement nor exclusion. 2. Decreased visual function (e.g. metamorphopsia or other visual symptom) that is attributed to VMT. Examples of visual symptoms include: a) Distortion and/or reduction in visual acuity b) Recognized difficulty with reading, driving, or using a computer c) Patient recognized interference with quality of life because of a and/or b. c. Visual acuity letter score of at least 19 (approximate Snellen equivalent 20/400 or better) and at most 78 (20/32 or worse) d. Investigator and participant willing to wait 6 months before surgical intervention, provided visual acuity remains stable • An eye that requires prompt treatment for VMT should not be enrolled Exclusion e. Other ocular condition that might affect visual acuity during the course of the study or require intraocular treatment (e.g., retinal vein occlusion, substantial age-related macular degeneration, or macular edema induced by a condition other than VMT) • If diabetic retinopathy is present, severity level must be microaneurysms only or better (= diabetic retinopathy severity level 20) • Presence of drusen is acceptable; however, eyes with geographic atrophy or neovascular age-related macular degeneration involving the macula are excluded f. High level of myopia (spherical equivalent of -8.00 diopters or more myopic if phakic or retinal abnormalities consistent with pathologic myopia if phakic or pseudophakic) g. History of prior gas injection, ocriplasmin injection, or intraocular injection for any reason h. History of prior vitrectomy i. History of uncontrolled glaucoma • IOP must be <30 mmHg, with no more than one topical glaucoma medication, and no documented glaucomatous field loss for the eye to be eligible j. History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 4 months or major ocular surgery anticipated within the next 6 months following randomization k. History of YAG capsulotomy performed within 4 months prior to randomization l. Aphakia or anterior chamber intraocular lens m. Exam evidence of severe external ocular infection, including conjunctivitis, chalazion, or substantial blepharitis n. Uveitis o. Presence of any macular hole or lamellar hole (according to reading center grading) p. Retinal history or pathology that might predispose an eye to an increased risk of retinal detachment from the procedure • Untreated retinal tears, not retinal holes, are an exclusion. It is up to the investigator to determine whether extent of lattice degeneration or other pathology might increase the risk of retinal detachment. q. Any contraindication to paracentesis (e.g., history of narrow angle glaucoma) r. Lenticular or zonular instability

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Pneumatic Vitreolysis (C3F8 injection)
Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.
Other:
Observation
No intervention; sham injection only

Locations

Country Name City State
United States Western Carolina Clinical Research, LLC Asheville North Carolina
United States Southeast Retina Center, PC Augusta Georgia
United States Austin Retina Associates Austin Texas
United States Retina Research Center Austin Texas
United States Valley Eye Physicians and Surgeons Ayer Massachusetts
United States Elman Retina Group, PA Baltimore Maryland
United States Retina Associates of Cleveland, Inc Beachwood Ohio
United States Gailey Eye Clinic Bloomington Illinois
United States Joslin Diabetes Center Boston Massachusetts
United States Retinal Diagnostic Center Campbell California
United States Charlotte Eye, Ear, Nose, and Throat Assoc., PA Charlotte North Carolina
United States Southeastern Retina Associates Chattanooga Tennessee
United States University of Illinois at Chicago Medical Center Chicago Illinois
United States Retina Vitreous Center Edmond Oklahoma
United States Oregon Retina, LLP Eugene Oregon
United States National Ophthalmic Research Institute Fort Myers Florida
United States Retina Specialists of Michigan Grand Rapids Michigan
United States Atlantis Eye Care Huntington Beach California
United States Raj K. Maturi, M.D., P.C. Indianapolis Indiana
United States University of Florida College of Med., Dept of Ophthalmology, Jacksonville Hlth Sci Ctr Jacksonville Florida
United States Southeastern Retina Associates, PC Knoxville Tennessee
United States Florida Retina Consultants Lakeland Florida
United States Northern California Retina Vitreous Associates Mountain View California
United States MaculaCare New York New York
United States Illinois Retina Associates, S.C. Oak Park Illinois
United States East Bay Retina Consultants, Inc Oakland California
United States Florida Retina Institute Orlando Florida
United States Mid-America Retina Consultants, P.A. Overland Park Kansas
United States Paducah Retinal Center Paducah Kentucky
United States Southern California Desert Retina Consultants, MC Palm Desert California
United States Southeast Eye Institute, PA dba Eye Associates of Pinellas Pinellas Park Florida
United States Retina Northwest, PC Portland Oregon
United States Mayo Clinic Department of Opthalmology Rochester Minnesota
United States The Retina Institute Saint Louis Missouri
United States Retinal Consultants of San Antonio San Antonio Texas
United States Thomas Eye Group Sandy Springs Georgia
United States Sarasota Retina Institute Sarasota Florida
United States Spokane Eye Clinic Spokane Washington
United States Wolfe Eye Clinic West Des Moines Iowa
United States Eye Associates of Northeast Louisiana dba Haik Humble Eye Center West Monroe Louisiana
United States Vitreo-Retinal Associates, PC Worcester Massachusetts

Sponsors (3)

Lead Sponsor Collaborator
Jaeb Center for Health Research National Eye Institute (NEI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of Eyes With Central Vitreomacular Traction Release Without Rescue Vitrectomy at 24 Weeks
Secondary Number of Eyes With Rescue Treatment Before the 24-week Visit up to 24 weeks
Secondary Number of Eyes With Rescue Vitrectomy Completed Before the 24-week Visit or Planned at the 24 Week Visit scheduled rescue vitrectomy must be completed within the subsequent 12 weeks. through 24 Weeks
Secondary Number of Eyes With Central Vitreomacular Traction Status up to 24 weeks
Secondary Mean Change in E-ETDRS Visual Acuity Letter Score From Baseline Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/10) to 0 letters (Snellen equivalent <20/800). Higher scores indicate better visual acuity and lower scores indicate worse visual acuity. Baseline to 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT06038968 - Methotrexate Infusion and Intrasilicone Injection During Diabetic Vitrectomy Early Phase 1
Terminated NCT04300881 - Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists) Phase 2
Active, not recruiting NCT01966328 - A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Attachment Phase 1
Recruiting NCT02290795 - Vitreopapillary Interface and Optic Disc Morphology N/A
Completed NCT05287269 - Ocular Coherence Tomography During Cataract Assessment
Completed NCT02322229 - Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion Phase 4
Completed NCT05517473 - Efficacy and Safety Evaluation of MONOBLUE DUAL View and MONOBLUE ILM View Vital Stains
Completed NCT01162356 - Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study N/A
Recruiting NCT05588037 - Combined Vitrectomy and Femtosecond Laser-assisted Cataract Surgery N/A
Completed NCT00435539 - A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt) Phase 2
Recruiting NCT00892619 - Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel N/A
Completed NCT02035748 - Assessment of Patients Treated With JETREA® for Vitreomacular Traction Phase 4
Recruiting NCT05860985 - Zeiss RESIGHT Disposable Lenses Evaluation Study N/A